Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
INFU vs HCSG vs CCRN vs ADUS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
INFU vs HCSG vs CCRN vs ADUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $181M | $1.60B | $423M | $1.81B |
| Revenue (TTM) | $142M | $1.84B | $761M | $1.45B |
| Net Income (TTM) | $8M | $59M | $-99M | $100M |
| Gross Margin | 56.7% | 13.3% | 18.2% | 32.5% |
| Operating Margin | 9.1% | 3.0% | -0.9% | 9.8% |
| Forward P/E | 21.5x | 20.8x | 133.8x | 14.1x |
| Total Debt | $3M | $25M | $2M | $209M |
| Cash & Equiv. | $3M | $161M | $109M | $82M |
INFU vs HCSG vs CCRN vs ADUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| InfuSystem Holdings… (INFU) | 100 | 77.2 | -22.8% |
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
| Cross Country Healt… (CCRN) | 100 | 215.7 | +115.7% |
| Addus HomeCare Corp… (ADUS) | 100 | 98.3 | -1.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INFU vs HCSG vs CCRN vs ADUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INFU is the #2 pick in this set and the best alternative if momentum and efficiency is your priority.
- +88.6% vs ADUS's -13.4%
- 7.9% ROA vs CCRN's -19.8%, ROIC 12.5% vs -0.9%
HCSG plays a supporting role in this comparison — it may shine differently against other peers.
CCRN is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
- Beta 0.78, current ratio 3.78x
ADUS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 0.58
- Rev growth 23.2%, EPS growth 23.2%, 3Y rev CAGR 14.4%
- 399.9% 10Y total return vs INFU's 159.0%
- 23.2% revenue growth vs CCRN's -21.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.2% revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (14.1x vs 133.8x) | |
| Quality / Margins | 6.9% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.58 vs INFU's 1.50 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +88.6% vs ADUS's -13.4% | |
| Efficiency (ROA) | 7.9% ROA vs CCRN's -19.8%, ROIC 12.5% vs -0.9% |
INFU vs HCSG vs CCRN vs ADUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
INFU vs HCSG vs CCRN vs ADUS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CCRN leads in 1 of 6 categories
INFU leads 1 • HCSG leads 1 • ADUS leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — INFU and ADUS each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCSG is the larger business by revenue, generating $1.8B annually — 12.9x INFU's $142M. ADUS is the more profitable business, keeping 6.9% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, ADUS holds the edge at +7.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $142M | $1.8B | $761M | $1.4B |
| EBITDAEarnings before interest/tax | $23M | $72M | $9M | $159M |
| Net IncomeAfter-tax profit | $8M | $59M | -$99M | $100M |
| Free Cash FlowCash after capex | $22M | $139M | $41M | $137M |
| Gross MarginGross profit ÷ Revenue | +56.7% | +13.3% | +18.2% | +32.5% |
| Operating MarginEBIT ÷ Revenue | +9.1% | +3.0% | -0.9% | +9.8% |
| Net MarginNet income ÷ Revenue | +5.6% | +3.2% | -13.0% | +6.9% |
| FCF MarginFCF ÷ Revenue | +15.4% | +7.6% | +5.4% | +9.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.0% | +6.6% | -100.0% | +7.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.0% | +175.0% | -6.0% | +17.2% |
Valuation Metrics
CCRN leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 18.7x trailing earnings, ADUS trades at a 35% valuation discount to INFU's 28.9x P/E. On an enterprise value basis, INFU's 7.2x EV/EBITDA is more attractive than CCRN's 23.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $181M | $1.6B | $423M | $1.8B |
| Enterprise ValueMkt cap + debt − cash | $181M | $1.5B | $317M | $1.9B |
| Trailing P/EPrice ÷ TTM EPS | 28.90x | 27.54x | -4.47x | 18.67x |
| Forward P/EPrice ÷ next-FY EPS est. | 21.54x | 20.83x | 133.84x | 14.12x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.93x |
| EV / EBITDAEnterprise value multiple | 7.19x | 22.38x | 23.75x | 12.52x |
| Price / SalesMarket cap ÷ Revenue | 1.26x | 0.87x | 0.40x | 1.28x |
| Price / BookPrice ÷ Book value/share | 3.30x | 3.19x | 1.31x | 1.65x |
| Price / FCFMarket cap ÷ FCF | 7.59x | 11.49x | 10.55x | 17.48x |
Profitability & Efficiency
INFU leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
INFU delivers a 14.0% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ADUS's 0.19x. On the Piotroski fundamental quality scale (0–9), INFU scores 8/9 vs CCRN's 6/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +14.0% | +11.8% | -27.1% | +9.3% |
| ROA (TTM)Return on assets | +7.9% | +7.3% | -19.8% | +7.0% |
| ROICReturn on invested capital | +12.5% | +9.0% | -0.9% | +8.8% |
| ROCEReturn on capital employed | +14.3% | +7.7% | -0.8% | +10.9% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 7 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.06x | 0.05x | 0.01x | 0.19x |
| Net DebtTotal debt minus cash | $241,000 | -$136M | -$106M | $127M |
| Cash & Equiv.Liquid assets | $3M | $161M | $109M | $82M |
| Total DebtShort + long-term debt | $3M | $25M | $2M | $209M |
| Interest CoverageEBIT ÷ Interest expense | 13.65x | 33.02x | -1.39x | 14.45x |
Total Returns (Dividends Reinvested)
Evenly matched — HCSG and ADUS each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ADUS five years ago would be worth $10,002 today (with dividends reinvested), compared to $4,297 for INFU. Over the past 12 months, INFU leads with a +88.6% total return vs ADUS's -13.4%. The 3-year compound annual growth rate (CAGR) favors HCSG at 14.1% vs CCRN's -17.7% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +6.8% | +28.6% | +62.4% | -8.7% |
| 1-Year ReturnPast 12 months | +88.6% | +55.8% | -5.4% | -13.4% |
| 3-Year ReturnCumulative with dividends | +2.8% | +48.6% | -44.3% | +16.3% |
| 5-Year ReturnCumulative with dividends | -57.0% | -21.1% | -22.5% | +0.0% |
| 10-Year ReturnCumulative with dividends | +159.0% | -26.8% | -10.5% | +399.9% |
| CAGR (3Y)Annualised 3-year return | +0.9% | +14.1% | -17.7% | +5.2% |
Risk & Volatility
Evenly matched — HCSG and ADUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADUS is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than INFU's 1.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCSG currently trades 91.5% from its 52-week high vs ADUS's 78.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.50x | 1.12x | 0.78x | 0.58x |
| 52-Week HighHighest price in past year | $11.04 | $24.39 | $14.99 | $124.44 |
| 52-Week LowLowest price in past year | $4.70 | $12.66 | $7.43 | $90.89 |
| % of 52W HighCurrent price vs 52-week peak | +81.2% | +91.5% | +87.3% | +78.2% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 61.8 | 53.1 | 49.3 |
| Avg Volume (50D)Average daily shares traded | 121K | 676K | 552K | 236K |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: INFU as "Buy", HCSG as "Hold", CCRN as "Hold", ADUS as "Buy". Consensus price targets imply 67.4% upside for INFU (target: $15) vs -18.9% for CCRN (target: $11).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | $15.00 | $24.50 | $10.61 | $128.67 |
| # AnalystsCovering analysts | 3 | 15 | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 20 | 1 | 2 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +6.1% | +3.9% | +1.6% | 0.0% |
CCRN leads in 1 of 6 categories (Valuation Metrics). INFU leads in 1 (Profitability & Efficiency). 3 tied.
INFU vs HCSG vs CCRN vs ADUS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INFU or HCSG or CCRN or ADUS a better buy right now?
For growth investors, Addus HomeCare Corporation (ADUS) is the stronger pick with 23.
2% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Addus HomeCare Corporation (ADUS) offers the better valuation at 18. 7x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate InfuSystem Holdings, Inc. (INFU) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INFU or HCSG or CCRN or ADUS?
On trailing P/E, Addus HomeCare Corporation (ADUS) is the cheapest at 18.
7x versus InfuSystem Holdings, Inc. at 28. 9x. On forward P/E, Addus HomeCare Corporation is actually cheaper at 14. 1x.
03Which is the better long-term investment — INFU or HCSG or CCRN or ADUS?
Over the past 5 years, Addus HomeCare Corporation (ADUS) delivered a total return of +0.
0%, compared to -57. 0% for InfuSystem Holdings, Inc. (INFU). Over 10 years, the gap is even starker: ADUS returned +399. 9% versus HCSG's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INFU or HCSG or CCRN or ADUS?
By beta (market sensitivity over 5 years), Addus HomeCare Corporation (ADUS) is the lower-risk stock at 0.
58β versus InfuSystem Holdings, Inc. 's 1. 50β — meaning INFU is approximately 161% more volatile than ADUS relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 19% for Addus HomeCare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — INFU or HCSG or CCRN or ADUS?
By revenue growth (latest reported year), Addus HomeCare Corporation (ADUS) is pulling ahead at 23.
2% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, ADUS leads at 14. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INFU or HCSG or CCRN or ADUS?
Addus HomeCare Corporation (ADUS) is the more profitable company, earning 6.
7% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 6. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADUS leads at 9. 7% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — INFU leads at 56. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INFU or HCSG or CCRN or ADUS more undervalued right now?
On forward earnings alone, Addus HomeCare Corporation (ADUS) trades at 14.
1x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 119. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INFU: 67. 4% to $15. 00.
08Which pays a better dividend — INFU or HCSG or CCRN or ADUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is INFU or HCSG or CCRN or ADUS better for a retirement portfolio?
For long-horizon retirement investors, Addus HomeCare Corporation (ADUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
58), +399. 9% 10Y return). InfuSystem Holdings, Inc. (INFU) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADUS: +399. 9%, INFU: +159. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INFU and HCSG and CCRN and ADUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INFU is a small-cap quality compounder stock; HCSG is a small-cap quality compounder stock; CCRN is a small-cap quality compounder stock; ADUS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.